Alberto Cruz‐Bermúdez

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio, Ernest Nadal, Amelia Insa et al. · The Lancet Oncology · 2020 · 828 citations

Medicine, Oncology, Pharmacology +14

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

Mariano Provencio, Ernest Nadal, J.L. González-Larriba et al. · New England Journal of Medicine · 2023 · 450 citations · Full text

Medicine, Oncology, Surgery +17

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Mariano Provencio, Roberto Serna‐Blasco, Ernest Nadal et al. · Journal of Clinical Oncology · 2022 · 335 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition

Alberto Cruz‐Bermúdez, Raquel Laza‐Briviesca, Ramiro J. Vicente-Blanco et al. · Free Radical Biology and Medicine · 2019 · 215 citations · Full text

Medicine, Oncology, Pharmacology +16

Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling

Alberto Cruz‐Bermúdez, Raquel Laza‐Briviesca, Ramiro J. Vicente-Blanco et al. · Free Radical Biology and Medicine · 2018 · 140 citations · Full text

Medicine, Cancer Biology, Oncology +17